Efficacy and safety of ziltivekimab in patients with chronic kidney disease susceptible to inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials

HIGHLIGHTS

• What: Detailed characteristics of the studies are presented in Tables 1, 2 and 3, while the baseline characteristics of the patients are provided in Table 4. The aim of the trial was to assess the safety of three escalating doses of ziltivekimab by reviewing adverse events (AEs) and laboratory results Ridker Pergola 12 weeks
• Who: Amr Elrosasy from the Meta‑regression A meta-regression was carried out to determine whether the dosage of ziltivekimab affected the endpoint resultsPrior to these meta-regression analyses, we conducted a conventional pairwise meta-analysis. This analysis utilized OpenMeta [Analyst . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.